Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone controlled-release - Chiesi

Next Previous
Drug Profile

Beclometasone controlled-release - Chiesi

Alternative Names: Beclomethasone controlled-release - Chiesi; Beclomethasone dipropionate controlled-release - Chiesi; CHF-1514; Clipper; EUR-1073

Latest Information Update: 19 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Developer Chiesi Farmaceutici; Eurand
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 16 May 2017 Chiesi initiates enrolment in the BeCalCU phase III trial for Ulcerative colitis in Spain (EudraCT2017-000330-61)
  • 03 Feb 2014 Aptalis has been acquired by Forest Laboratories
  • 11 Feb 2011 Eurand has been acquired and merged into Axcan Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top